As­traZeneca push­es back OS read­out on MYS­TIC to H2; An­thera shares oblit­er­at­ed in re­peat PhI­II flop

→ The much-an­tic­i­pat­ed over­all sur­vival da­ta of As­traZeneca’s $AZN piv­otal lung can­cer tri­al will be de­liv­ered lat­er than ex­pect­ed, the UK drug­mak­er an­nounced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER